Loading
Saruparib is an experimental small-molecule drug from AstraZeneca in phase 3 trials for prostate cancer, ovarian cancer and non-small-cell lung cancer, aimed at PARP.
Saruparib (AZD5305) is a small-molecule drug developed by AstraZeneca. Its target is PARP (the sponsor names PARP (poly(ADP-ribose) polymerase)). The sponsor states: Saruparib (AZD5305) is an oral PARP inhibitor, studied added to androgen deprivation therapy (with or without abiraterone) in patients with BRCA-mutated prostate cancer. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06952803 (A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation) and NCT06120491 (Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents), in prostate cancer, ovarian cancer, non-small-cell lung cancer and endometrial cancer. The largest, NCT06120491, plans to enrol 1898 participants (actual) with primary completion expected 2027-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Saruparib (AZD5305) is an oral PARP inhibitor, studied added to androgen deprivation therapy (with or without abiraterone) in patients with BRCA-mutated prostate cancer. Connects to PARP.
1.Saruparib slips into a pocket on PARP.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Saruparib" OR ABSTRACT:"Saruparib" OR TITLE:"AZD5305" OR ABSTRACT:"AZD5305") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Saruparib, not a curated reading list.
Shares Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors, A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies, PARP, Endometrial cancer and the tag pipeline.
Shares A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs, AstraZeneca, Prostate cancer and the tag pipeline.
Shares Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors, AstraZeneca, Ovarian cancer and the tag pipeline.
Shares Platinum-sensitive ovarian cancer, AstraZeneca, Ovarian cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Endometrial cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer and the tag pipeline.